Multipolymer microsphere delivery of SARS-CoV-2 antigens
Copyright © 2022. Published by Elsevier Ltd..
Effective antigen delivery facilitates antiviral vaccine success defined by effective immune protective responses against viral exposures. To improve severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigen delivery, a controlled biodegradable, stable, biocompatible, and nontoxic polymeric microsphere system was developed for chemically inactivated viral proteins. SARS-CoV-2 proteins encapsulated in polymeric microspheres induced robust antiviral immunity. The viral antigen-loaded microsphere system can preclude the need for repeat administrations, highlighting its potential as an effective vaccine. STATEMENT OF SIGNIFICANCE: Successful SARS-CoV-2 vaccines were developed and quickly approved by the US Food and Drug Administration (FDA). However, each of the vaccines requires boosting as new variants arise. We posit that injectable biodegradable polymers represent a means for the sustained release of emerging viral antigens. The approach offers a means to reduce immunization frequency by predicting viral genomic variability. This strategy could lead to longer-lasting antiviral protective immunity. The current proof-of-concept multipolymer study for SARS-CoV-2 achieve these metrics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Acta biomaterialia - 158(2023) vom: 01. März, Seite 493-509 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shahjin, Farah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 23.02.2023 Date Revised 16.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.actbio.2022.12.043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350923523 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350923523 | ||
| 003 | DE-627 | ||
| 005 | 20240116231840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.actbio.2022.12.043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM350923523 | ||
| 035 | |a (NLM)36581007 | ||
| 035 | |a (PII)S1742-7061(22)00853-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shahjin, Farah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multipolymer microsphere delivery of SARS-CoV-2 antigens |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2023 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Ltd. | ||
| 520 | |a Effective antigen delivery facilitates antiviral vaccine success defined by effective immune protective responses against viral exposures. To improve severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigen delivery, a controlled biodegradable, stable, biocompatible, and nontoxic polymeric microsphere system was developed for chemically inactivated viral proteins. SARS-CoV-2 proteins encapsulated in polymeric microspheres induced robust antiviral immunity. The viral antigen-loaded microsphere system can preclude the need for repeat administrations, highlighting its potential as an effective vaccine. STATEMENT OF SIGNIFICANCE: Successful SARS-CoV-2 vaccines were developed and quickly approved by the US Food and Drug Administration (FDA). However, each of the vaccines requires boosting as new variants arise. We posit that injectable biodegradable polymers represent a means for the sustained release of emerging viral antigens. The approach offers a means to reduce immunization frequency by predicting viral genomic variability. This strategy could lead to longer-lasting antiviral protective immunity. The current proof-of-concept multipolymer study for SARS-CoV-2 achieve these metrics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Antiviral immunity | |
| 650 | 4 | |a Multilayerpolymer | |
| 650 | 4 | |a Polymeric microspheres | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Slow-controlled antigen release | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Patel, Milankumar |e verfasserin |4 aut | |
| 700 | 1 | |a Machhi, Jatin |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Jacob D |e verfasserin |4 aut | |
| 700 | 1 | |a Nayan, Mohammad Ullah |e verfasserin |4 aut | |
| 700 | 1 | |a Yeapuri, Pravin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Waight, Emiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Mahmudul |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmoaty, Mai Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Dash, Prasanta K |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, You |e verfasserin |4 aut | |
| 700 | 1 | |a Andreu, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Gendelman, Howard E |e verfasserin |4 aut | |
| 700 | 1 | |a Kevadiya, Bhavesh D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta biomaterialia |d 2005 |g 158(2023) vom: 01. März, Seite 493-509 |w (DE-627)NLM162829779 |x 1878-7568 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2023 |g day:01 |g month:03 |g pages:493-509 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.actbio.2022.12.043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2023 |b 01 |c 03 |h 493-509 | ||